Lysinuric protein intolerance (LPI) is a very rare inherited multisystem condition caused by disturbance in amino acid metabolism.
Comprehensive, easy-to-understand information about this condition
How we create this content →Report Generation Failed
We couldn't automatically generate the report. This may be due to temporary service issues.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease
Aduro BioTech, Inc.
Other
Advaxis, Inc.
Other
Avstera Therapeutics Corp.
Other
Binhui Biopharmaceutical Co., Ltd.
Other
Bioverativ Therapeutics, Inc.
Other
Bristol-Myers Squibb Company
Other
Brucells SA
Other
Celgene Corporation
Other
Cook Biotech Incorporated
Other
Eisai Inc.
Other
GammaCan Ltd.
Other
Gradalis, Inc.
Other
Linnaeus Therapeutics, Inc.
Other
Lumos Pharma
Other
MedImmune, LLC
Other
Morphogenesis, Inc.
Other
Nektar Therapeutics
Other
Polynoma LLC
Other
Regeneron Pharmaceuticals, Inc.
Other
TCRx (KeShiHua.Shenzhen) Therapeutics Ltd.
Other
Wyeth Pharmaceuticals, Inc.
Other